/

MaxCyte, Inc.

MXCT US

MXCT USMaxCyte, Inc.

United States Composite

3.83

USD

+0.05

(+1.32%)

-0.37EPS Dil.

-10.43P/E

398.17MMarket Cap

Next Earnings

May 8

Held by Insiders

1.30%

Held by Institutions

75.95%

YTD Yield

-19.35%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

- -

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

103

104

Market Capitalization

473

323

489

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

237

214

190

Cash, Cash Equivalents & STI

216

190

168

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

20.10%

20.19%

-6.82%

Net Income, GAAP

-65.31%

-35.95%

-58.33%

Free Cash Flow

-NaN%

-26.61%

24.24%

Total Cash Common Dividend

- -

Total Equity

78.06%

167.45%

-8.66%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

2023

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.09

-0.05

-0.03

-0.05

-0.21

2022

-0.04

-0.08

-0.06

-0.05

-0.23

2023

-0.11

-0.10

-0.11

-0.05

-0.37

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. Maher Masoud
Full Time Employees: 143
Sector: Healthcare
Industry: Medical Devices
Address: 9713 Key West Avenue Rockville MD United States 20850
IPO Date: Mar 29, 2016
Website: www.maxcyte.com
Business: MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Company News

Yahoo
16 days ago
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Yahoo
23 days ago
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
Yahoo
a month ago
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Yahoo
2 months ago
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
Yahoo
2 months ago
MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates
Yahoo
2 months ago
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript
Yahoo
2 months ago
MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years
Yahoo
2 months ago
MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023
Yahoo
2 months ago
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
Yahoo
2 months ago
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

Company Description

CEO: Mr. Maher Masoud
Full Time Employees: 143
Sector: Healthcare
Industry: Medical Devices
Address: 9713 Key West Avenue Rockville MD United States 20850
IPO Date: Mar 29, 2016
Website: www.maxcyte.com
Business: MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Company News

Yahoo
16 days ago
We Think MaxCyte (LON:MXCT) Can Afford To Drive Business Growth
Yahoo
23 days ago
MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
Yahoo
a month ago
MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
Yahoo
2 months ago
Downgrade: Here's How Analysts See MaxCyte, Inc. (LON:MXCT) Performing In The Near Term
Yahoo
2 months ago
MaxCyte, Inc. (LON:MXCT) Just Reported And Analysts Have Been Cutting Their Estimates
Yahoo
2 months ago
MaxCyte, Inc. (NASDAQ:MXCT) Q4 2023 Earnings Call Transcript
Yahoo
2 months ago
MaxCyte's (LON:MXCT) investors will be pleased with their notable 68% return over the last five years
Yahoo
2 months ago
MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023
Yahoo
2 months ago
MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance
Yahoo
2 months ago
MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results